| Affiliation: | 1. Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN;2. Division of Cardiovascular Surgery, Mayo Clinic, Rochester, MN;3. Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN;4. Division of General Internal Medicine, Mayo Clinic, Rochester, MN;5. Division of Hematology and Medical Oncology, Mayo Clinic Hospital, Phoenix, AZ;6. Division of Cardiovascular and Thoracic Surgery, Mayo Clinic Hospital, Phoenix, AZ;7. Augsburg College, Minneapolis, MN;8. University of Wisconsin, Madison;9. MacLean Center for Clinical Medical Ethics, University of Chicago, Chicago, IL |
| Abstract: | ObjectivesTo describe the characteristics of patients who undergo withdrawal of total artificial heart support and to explore the ethical aspects of withdrawing this life-sustaining treatment.Patients and MethodsWe retrospectively reviewed the medical records of all adult recipients of a total artificial heart at Mayo Clinic from the program's inception in 2007 through June 30, 2015. Management of other life-sustaining therapies, approach to end-of-life decision making, engagement of ethics and palliative care consultation, and causes of death were analyzed.ResultsOf 47 total artificial heart recipients, 14 patients or their surrogates (30%) requested withdrawal of total artificial heart support. No request was denied by treatment teams. All 14 patients were supported with at least 1 other life-sustaining therapy. Only 1 patient was able to participate in decision making.ConclusionIt is widely held to be ethically permissible to withdraw a life-sustaining treatment when the treatment no longer meets the patient's health care–related goals (ie, the burdens outweigh the benefits). These data suggest that some patients, surrogates, physicians, and other care providers believe that this principle extends to the withdrawal of total artificial heart support. |
